Xarxa de bancs de tumors de Catalunya

  • Increase font size
  • Default font size
  • Decrease font size

Hospital Vall d'Hebron

Correu electrònic Imprimeix PDF

Investigador Responsable: Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la

Descripció

Nom del Banc: Biobanc HUVH - Hospital Universitari Vall d'Hebron, Barcelona

Centre: Servei d'Anatomia Patològica-HUVH, Barcelona

Institució:  Hospital Universitari Vall d'Hebron (HUVH) y Vall d'Hebron Institut de Recerca, Barcelona

Banc de tumors creat l'any 2004 que consta de teixit congelat tumoral i sa procedents d'excedents d'intervencions quirúrgiques.

 

Personal

Nom Títol Categoria

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Dra.

Directora Biobanc HUVH

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Dr

Patòleg

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Dra.

Patòleg

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Dr.

Biòleg

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la

Lic en Biologia Técnic de laboratori
Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Tècnic

Técnic de laboratori

Activitats

  • Selecció, congelació, emmagatzematge i distribució de mostres congelades de tumors.
  • Extracció de DNA, RNA i proteïna de teixit congelat i parafinat.
  • Disseny i fabricació de matrius de teixit (Tissue Microarrays o TMAs).

Fons

  • Fragments de teixit congelat
  • Fragments de teixit congelat inclòs en OCT

Publicacions

  • Emerging role for the voltage-dependent K+ channel Kv1.5 in B-lymphocyte physiology: expression associated with human lymphoma malignancy. Vallejo-Gracia A, Bielanska J, Hernández-Losa J, Castellví J, Ruiz-Marcellan MC, Ramón Y Cajal S, Condom E, Manils J, Soler C, Comes N, Ferreres JC, Felipe A. J Leukoc Biol 2013. DOI: 10.1189/jlb.0213094.
  • Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis. Ferrándiz-Pulido C, Masferrer E, de Torres I, Lloveras B, Hernandez-Losa J, Mojal S, Salvador C, Morote J, Ramon y Cajal S, Pujol RM, Garcia-Patos V, Toll A. J Am Acad Dermatol 2013; 68(1):73-82.
  • Brush border myosin Ia has tumor suppressor activity in the intestine. Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D. Proc Natl Acad Sci USA 2012; 109(5):1530-5.

  • BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Serrano C, Simonetti S, Hernández-Losa J, Valverde C, Carrato C, Bagué S, Orellana R, Somoza R, Moliné T, Carles J, Huguet P, Romagosa C, Ramón y Cajal S. Histopathology 2013; 62(3):499-504. DOI: 10.1111/his.12021.

  • ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F. Int J Cancer 2013; 133(1):235-46. DOI: 10.1002/ijc.28009.

  • Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodriguez-Freixinos V, Canela M, Ramon y Cajal S, Felip E. PLoS One 2013; 8(1):e52261.

  • mTOR Signaling Pathway in Penile Squamous Cell Carcinoma: pmTOR and peIF4E Over Expression Correlate with Aggressive Tumor Behavior. Ferrandiz-Pulido C, Masferrer E, Toll A, Hernandez-Losa J, Mojal S, Pujol RM, Ramon Y Cajal S, de Torres I, Garcia-Patos V. J Urol. 2013. DOI: pii: S0022-5347(13)04585-0.

  • Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. Espinosa-Bravo M, Sansano I, Pérez-Hoyos S, Ramos M, Sancho M, Xercavins J, Rubio IT, Peg V. Eur J Surg Oncol 2013; 39(7):766-73.

  • A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J. Oncogene 2013; 32(11):1452-9.

  • Dual regulation of Myc by Abl. Sanchez-Arévalo Lobo VJ, Doni M, Verrecchia A, Sanulli S, Fagà G, Piontini A, Bianchi M, Conacci-Sorrell M, Mazzarol G, Peg V, Losa JH, Ronchi P, Ponzoni M, Eisenman RN, Doglioni C, Amati B. Oncogene 2013. DOI: 10.1038/onc.2012.621.

  • Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression. Cuadros T, Trilla E, Vilà MR, de Torres I, Vilardell J, Messaoud NB, Salcedo M, Sarró E, López-Hellin J, Blanco A, Mir C, Ramón y Cajal S, Itarte E, Morote J, Meseguer A. Eur J Cancer 2013; 49(8):2034-47. DOI: 10.1016/j.ejca.2012.12.020.

  • SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. Ordóñez-Morán P, Irmisch A, Barbáchano A, Chicote I, Tenbaum S, Landolfi S, Tabernero J, Huelsken J, Muñoz A, Pálmer HG. Oncogene 2013. DOI: 10.1038/onc.2013.140.

  • Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Marqués N, Sesé M, Cánovas V, Valente F, Bermudo R, de Torres I, Fernández Y, Abasolo I, Fernández PL, Contreras H, Castellón E, Celià-Terrassa T, Méndez R, Ramón Y Cajal S, Thomson TM, Paciucci R. Oncogene 2013. DOI: 10.1038/onc.2013.51.

  • MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, Lleonart M, Roncador G, Marin JJ, Carnero A. PLoS One 2013; 8(2):e56169. DOI: 10.1371/journal.pone.0056169.

  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J. J Clin Invest 2013; 123(6):2551-63. DOI: 10.1172/JCI66343.

  • MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Sánchez-Espiridión B, Martín-Moreno AM, Montalbán C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M, Menarguez J, Sabín P, Ruiz-Marcellán MC, Lopez A, Sánchez-Godoy P, Burgos F, Santonja C, López JL, Piris MA, Garcia JF. Br J Haematol 2013; 162(3):336-47. DOI: 10.1111/bjh.12390.

  • Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines. Teixidó C, Marés R, Aracil M, Ramón Y Cajal S, Hernández-Losa J. PLoS One 2013; 8(1):e53645. DOI: 10.1371/journal.pone.0053645.
  • Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: Correlation with pathologic subtypes, p16(INK4a) expression, and prognosis. Ferrándiz-Pulido C, Masferrer E, de Torres I, Lloveras B, Hernandez-Losa J, Mojal S, Salvador C, Morote J, Ramon y Cajal S, Pujol RM, Garcia-Patos V, Toll A. J Am Acad Dermatol 2013; 68(1):73-82. DOI: 10.1016/j.jaad.2012.05.029.
  • Oxidative stress and cancer: An overview. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, Lleonart ME. Ageing Res Rev 2013; 12(1):376-90. DOI: 10.1016/j.arr.2012.10.004.
  • Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, Saura C, Peg V, Rovira A, Di Cosimo S. Breast 2013; 22(1):19-23. DOI: 10.1016/j.breast.2012.10.009.
  • BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Serrano C, Simonetti S, Hernández-Losa J, Valverde C, Carrato C, Bagué S, Orellana R, Somoza R, Moliné T, Carles J, Huguet P, Romagosa C, Ramón y Cajal S. Histopathology 2013; 62(3):499-504. DOI: 10.1111/his.12021.
  • The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model. Pons B, Peg V, Vázquez-Sánchez MA, López-Vicente L, Argelaguet E, Coch L, Martínez A, Hernández-Losa J, Armengol G, Ramon Y Cajal S. Int J Oncol 2011; 39(5):1337-45.
  • Increased voltage-dependent K(+) channel Kv1.3 and Kv1.5 expression correlates with leiomyosarcoma aggressiveness. Bielanska J, Hernández-Losa J, Moline T, Somoza R, Cajal SR, Condom E, Ferreres JC, Felipe A. Oncol Lett 2012; 4(2):227-30.
  • Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J. Mol Cancer Ther 2012 ; 11(9):2062-71.
  • A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J. Oncogene 2012. DOI: 10.1038/onc.2012.152.
  • β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S Jr, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG. Nat Med 2012; 18(6):892-901.
  • Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer. Llauradó M, Majem B, Castellví J, Cabrera S, Gil-Moreno A, Reventós J, Ruiz A. Mol Cancer Res 2012; 10(7):914-24.
  • EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosía SG, Mazorra F, Castillo ME, Lopez M, Pajares R, García JF, Mollejo M, Camacho FI, Ruiz-Marcellán C, Adrados M, Ortiz N, Franco R, Ortiz-Hidalgo C, Suarez-Gauthier A, Young KH, Piris MA. Mod Pathol 2012; 25(7):968-82.
  • Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Cedrés S, Montero MA, Martinez P, Martinez A, Rodríguez-Freixinós V, Torrejon D, Gabaldon A, Salcedo M, Ramon Y Cajal S, Felip E. Lung Cancer 2012; 77(1):192-8.
  • Differential expression of Kv1.3 and Kv1.5 voltage-dependent K+ channels in human skeletal muscle sarcomas. Bielanska J, Hernández-Losa J, Moline T, Somoza R, Ramón y Cajal S, Condom E, Ferreres JC, Felipe A. Cancer Invest 2012; 30(3):203-8.
  • USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. Nat Med 2012; 18(3):429-35.
  • Brush border myosin Ia has tumor suppressor activity in the intestine. Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D. Proc Natl Acad Sci U S A 2012; 109(5):1530-35.
  • Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Martín-Pérez D, Vargiu P, Montes-Moreno S, León EA, Rodríguez-Pinilla SM, Lisio LD, Martínez N, Rodríguez R, Mollejo M, Castellvi J, Pisano DG, Sánchez-Beato M, Piris MA. Leukemia 2012; 26(1):180-83.
  • ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Llauradó M, Abal M, Castellví J, Cabrera S, Gil-Moreno A, Pérez-Benavente A, Colás E, Doll A, Dolcet X, Matias-Guiu X, Vazquez-Levin M, Reventós J, Ruiz A. Int J Cancer 2012; 130(7):1532-43.
  • The EMT signaling pathways in endometrial carcinoma. Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martínez E, Llauradó M, Rigau M, Olivan M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellvi J, Garcia A, Ramon y Cajal S, Moreno-Bueno G, Dolcet X, Alameda F, Palacios J, Prat J, Doll A, Matias-Guiu X, Abal M, Reventos J. Clin Transl Oncol 2012; 14(10):715-20. DOI: 10.1007/s12094-012-0866-3.
  • Metabolic syndrome increases the risk of aggressive prostate cancer detection. Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, Doll A. BJU Int 2012. DOI: 10.1111/j.1464-410X.2012.11406.x.
  • ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Colas E, Muinelo-Romay L, Alonso-Alconada L, Llaurado M, Monge M, Barbazan J, Gonzalez M, Schoumacher M, Pedrola N, Ertekin T, Devis L, Ruiz A, Castellvi J, Doll A, Gil-Moreno A, Vazquez-Levin M, Lapyckyj L, Lopez-Lopez R, Robine S, Friederich E, Castro M, Reventos J, Vignjevic D, Abal M. Oncogene 2012; 31(45):4778-88. DOI: 10.1038/onc.2011.632.
  • ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Llauradó M, Abal M, Castellví J, Cabrera S, Gil-Moreno A, Pérez-Benavente A, Colás E, Doll A, Dolcet X, Matias-Guiu X, Vazquez-Levin M, Reventós J, Ruiz A. Int J Cancer 2011; 130(7):1532-43. DOI: 10.1002/ijc.26148.
  • Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. Mir MC, Trilla E, de Torres IM, Panizo A, Zlotta AR, Van Rhijn B, Morote J. BJU Int. 2011; 108(2 Pt 2):E71-6.
  • Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma.Martín-Pérez D, Vargiu P, Montes-Moreno S, León EA, Rodríguez-Pinilla SM, Lisio LD, Martínez N, Rodríguez R, Mollejo M, Castellvi J, Pisano DG, Sánchez-Beato M, Piris MA. Leukemia 2011; 26(1):180-83. DOI: 10.1038/leu.2011.189.
  • Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, Suarez R, Verge M, Marin JJ, Hernandez-Losa J, Ramon y Cajal S, Paz-Ares L, Carnero A. J Pathol 2011; 225(1):73-82.
  • Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors. Artero-Castro A, Castellvi J, García A, Hernández J, Ramón y Cajal S, Lleonart ME. Hum Pathol 2011; 42(2):194-203.
  • Molecular markers of endometrial carcinoma detected in uterine aspirates. Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, Eyzaguirre F, Gregorio J, Ruiz A, Llaurado M, Rigau M, Garcia M, Ertekin T, Montes M, Lopez-Lopez R, Carreras R, Xercavins J, Ortega A, Maes T, Rosell E, Doll A, Abal M, Reventos J, Gil-Moreno A. Int J Cancer 2011; 129(10):2435-44. DOI: 10.1002/ijc.25901.
  • PTOV1 is overexpressed in human high-grade malignant tumors. Fernández S, Mosquera JL, Alaña L, Sanchez-Pla A, Morote J, Ramón y Cajal S, Reventós J, de Torres I, Paciucci R. Virchows Arch 2011; 458(3):323-30.
  • Colon metastasis of lobular breast carcinoma. Landi F, Martí Gallostra M, Espin Basany E, Landolfi S, Armengol Carrasco M. Cir Esp 2011; 90(7):466-76. DOI: 10.1016/j.ciresp.2010.12.021.
  • Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J. BJU Int 2010; 105(2):202-07.
  • Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM. BJU Int 2010; 105(4):481-84.
  • Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Lopez-Beltran A, Amin MB, Oliveira PS, Montironi R, Algaba F, McKenney JK, de Torres I, Mazerolles C, Wang M, Cheng L. Am J Surg Pathol 2010; 34(3):371-76.
  • Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D. Clin Cancer Res 2010; 16(8):2375-82.
  • Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis]. Zafón C, Castellví J, Obiols G. Endocrinol Nutr 2010; 57(4):165-69.
  • Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Quiles MT, Arbós MA, Fraga A, de Torres IM, Reventós J, Morote J. Prostate 2010; 70(10):1044-53.
  • Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome. de la Torre J, Sabadell MD, Rojo F, Lirola JL, Salicru S, Reventos J, Ramón y Cajal S, Xercavins J. Eur J Obstet Gynecol Reprod Biol 2010; 151(1):72-6.
  • SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Barbáchano A, Ordóñez-Morán P, García JM, Sánchez A, Pereira F, Larriba MJ, Martínez N, Hernández J, Landolfi S, Bonilla F, Pálmer HG, Rojas JM, Muñoz A. Oncogene 2010; 29(34):4800-13.
  • A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón y Cajal S, Baselga J, Arribas J. Cancer Res 2010; 70(21):8537-46.
  • Differences in the Form of Presentation between Papillary Microcarcinomas and Papillary Carcinomas of Larger Size.Zafon C, Baena JA, Castellví J, Obiols G, Monroy G, Mesa J. J Thyroid Res 2010; 2011:639156.
  • Primary squamous cell carcinoma of the vagina: human papillomavirus detection, p16(INK4A) overexpression and clinicopathological correlations. Fuste V, del Pino M, Perez A, Garcia A, Torne A, Pahisa J, Ordi J. Histopathology 2010; 57(6):907-16.
  • Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, Raventós CX, Placer J, de Torres IM, Reventós J, Doll A. World J Urol 2010; 28(6):677-80.
  • Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores. Raventós CX, Orsola A, de Torres I, Cecchini L, Trilla E, Planas J, Morote J. Urol Int 2010; 84(2):153-58.

 

Equip i tècniques

  • 1 Sistema de congelació ràpida (Bright Clini-RF Rapid Freezer, Brigth Instruments)
  • 1 Equip de macrofotografia (MacroPath D, MILESTONE)
  • 1 Equip d'extracció d'ARN i ADN (QuickGene 810)
  • 1 Criòstat (CM1900, Leica)
  • 2 Robots extractor semi-automàtic d'extracció d'ADN i ARN (EZ1 Biorobot Qiagen) i 1 Qiasymphony QIAGEN)
  • 5 Arcons congeladors -80ºC
  • Sistema d'alarma local i remota (Sistema Syrius), amb sondes de registre de temperatura per a cada congelador
  • 2 Sistemes d'alimentació elèctrica independent de la xarxa (SAI)
  • 1 Equip per a la fabricació de matrius de teixit (Advanced Tissue Arrayer (CHEMICON))
  • 1 Equip d'immunohistoquímica automatitzada (BenchMarkXT, VENTANA)

Altres